Cardiome Pharma Corp. (COM.TO)
-Toronto 2.08 
0.08(4.00%) May 24, 1:29PM EDT
| Prev Close: | 2.00 |
|---|
| Open: | 2.00 |
|---|
| Bid: | 2.00 |
|---|
| Ask: | 2.07 |
|---|
| 1y Target Est: | 2.50 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 2.00 - 2.08 |
|---|
| 52wk Range: | 1.20 - 2.70 |
|---|
| Volume: | 702 |
|---|
| Avg Vol (3m): | 7,251 |
|---|
| Market Cap: | 25.94M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in CAD.
Headlines
- Cardiome Reports First Quarter ResultsCNW Group(Mon, May 13)
- Cardiome Reports First Quarter ResultsPR Newswire(Mon, May 13)
- Q1 2013 CARDIOME PHARMA CORP Earnings Release - Time Not SuppliedCCBN(Mon, May 13)
- Cardiome To Present At Bloom Burton & Co. Healthcare Investor ConferenceCNW Group(Fri, May 10)
- Cardiome To Present At Bloom Burton & Co. Healthcare Investor ConferencePR Newswire(Fri, May 10)
- Cardiome to Hold First Quarter 2013 Financial Results Conference Call on May 13CNW Group(Thu, May 9)
- Cardiome Accepts the Transfer of Sponsorship of U.S. and Canadian Vernakalant IV and Oral Regulatory Filings from MerckCNW Group(Thu, May 2)
- Cardiome Announces Worldwide Sales And Marketing Of BRINAVESS™CNW Group(Thu, Apr 25)
- Cardiome Announces Share Consolidation Effective April 12, 2013CNW Group(Fri, Apr 12)
- Cardiome Announces Shareholder Approval of Share ConsolidationCNW Group(Thu, Apr 4)
- Cardiome Appoints Jürgen Polifka, Ph.D., as General Manager, Sales and Marketing EuropeCNW Group(Tue, Apr 2)
- Cardiome Announces The Addition Of Dr. Steen Juul-Möller As Medical Director, EuropePR Newswire(Thu, Mar 28)
- Cardiome Announces The Addition Of Dr. Steen Juul-Möller As Medical Director, EuropeCNW Group(Thu, Mar 28)
- Cardiome Announces Changes to Senior Management TeamCNW Group(Tue, Mar 26)
- Cardiome Announces Changes to Senior Management TeamPR Newswire(Tue, Mar 26)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 59.95 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 0.21 |
|---|
| Quarterly EPS Est
(Mar-13)
: | N/A |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | -0.18 |
|---|
Business Summary
Cardiome Pharma Corp., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies that enhance the health of patients.
View More